Single photon emission computer tomography of dopamine transporters in monkeys and humans with 99mTc-TRODAT-1
- PMID: 15265382
Single photon emission computer tomography of dopamine transporters in monkeys and humans with 99mTc-TRODAT-1
Abstract
Background: The diagnosis of Parkinson's disease is presently based on non-specific symptoms. However, radionuclide dopamine transporters imaging can provide specific diagnostic tool for Parkinson's disease. This study was designed to investigate the effects of imaging of dopamine transporters with 99mTc-TRODAT-1 in early diagnosis or differential diagnosis of Parkinson's disease.
Methods: Nine normal monkeys were used to establish N-methyl-4-phenyl-1, 2, 3, 6-tetra-hydropyridine (MPTP) hemi-Parkinsonian animal models, and they were subjected to imaging. Twenty-nine patients with Parkinson's disease, 12 age-matched healthy volunteers, and 18 age-matched patients with Parkinson's syndrome were investigated. Single photon emission computer tomography (SPECT) was performed 3 hours after intravenous injection of 740 MBq 99mTc-TRODAT-1. Striatum specific uptake of 99mTc-TRODAT-1 was calculated according to the ratio of striatum (ST) to cerebellum (CB) in dopamine transporters uptake.
Results: In normal monkeys, bilateral ratio of ST/CB was 2.34 +/- 0.41. After the injection of MPTP, uptake rate of 99mTc-TRODAT-1 at damaged region was much lower than that at the contralateral region, resulting in a significant difference in the ratio of ST/CB (right: ST/CB = 1.73 +/- 0.35; left: ST/CB = 1.90 +/- 0.30), especially in hemi-Parkinsonian model monkeys (right: ST/CB = 1.29 +/- 0.17; left: ST/CB = 1.80 +/- 0.33). The ratios of ST/CB were 1.57 +/- 0.17 and 1.61 +/- 0.14 for the right and left respectively in the healthy volunteers, 1.04 +/- 0.29 and 1.06 +/- 0.30 in the age-matched patients with Parkinson's disease, and 1.56 +/- 0.17 and 1.59 +/- 0.18 in the age-matched patients with Parkinson's disease syndrome. A significant difference was noted between group of Parkinson's disease, normal controls and Parkinson's disease syndrome.
Conclusion: The results suggest that 99mTc-TRODAT-1 dopamine transporters SPECT has clinical application value in early diagnosis or differential diagnosis of Parkinson's disease.
Similar articles
-
Dopamine transporter binding in chronic manganese intoxication.J Neurol. 2003 Nov;250(11):1335-9. doi: 10.1007/s00415-003-0214-1. J Neurol. 2003. PMID: 14648150
-
Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents.J Med Chem. 1997 Jan 3;40(1):9-17. doi: 10.1021/jm960532j. J Med Chem. 1997. PMID: 9016323
-
Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.Synapse. 2001 Feb;39(2):101-8. doi: 10.1002/1098-2396(200102)39:2<101::AID-SYN1>3.0.CO;2-1. Synapse. 2001. PMID: 11180497
-
Imaging dopamine transporters in Parkinson's disease.Biomark Med. 2010 Oct;4(5):651-60. doi: 10.2217/bmm.10.86. Biomark Med. 2010. PMID: 20945978 Review.
-
Parkinson's disease: epidemiology, (differential) diagnosis, therapy, relation to dementia.Arzneimittelforschung. 1995 Mar;45(3A):386-9. Arzneimittelforschung. 1995. PMID: 7763330 Review.
Cited by
-
Age-related decline in motor behavior and striatal dopamine transporter in cynomolgus monkeys.J Neural Transm (Vienna). 2012 Aug;119(8):943-52. doi: 10.1007/s00702-012-0770-6. Epub 2012 Feb 11. J Neural Transm (Vienna). 2012. PMID: 22327353